Coherus BioSciences, Inc. (NASDAQ:CHRS), a commercial-stage biopharmaceutical company with a market capitalization of approximately $149 million, has undergone a significant transformation in recent ...

Health Canada has granted market authorisation to Takeda Canada for FRUZAQLA (fruquintinib) capsules to treat adults with ...

Takeda Canada Inc. ("Takeda") is pleased to announce that Health Canada has provided market authorization for FRUZAQLAtm (fruquintinib capsules), indicated for the treatment of adult patients with ...

Takeda Canada Inc. ("Takeda") is pleased to announce that Health Canada has provided market authorization for FRUZAQLA™ (fruquintinib capsules), indicated for the treatment of adult patients with ...

Key Takeaways Merck faces headwinds like declining sales of the HPV vaccine, Gardasil, and diabetes drug, Januvia. Merck ...

In diabetic kidney disease, fat accumulates in the kidneys, leading to lipotoxicity and kidney damage. A recently published ...

As the year unfolds the biotech industry will look closely at these ten first-in-class drugs on track to reach FDA approval ...

USA News Group News Commentary – As the new year begins, the American Association for Cancer Research (AACR) has highlighted ...

EYLEA HD® and EYLEA® remained the U.S. anti-VEGF category leader in 2024; aggregate U.S. net product sales were $6 billion for full-year 2024, up 1% based on preliminary (unaudited) results EYLEA HD ...

Truist initiated coverage on BioNTech SE (NASDAQ:BNTX), a famed COVID-19 vaccine maker, in collaboration with Pfizer Inc ...

© 2025 American Heart Association, Inc. Cardiovascular Research Center, New York University Langone Health, New York University Grossman School of Medicine. (A.A.C.N ...

Top-line Phase 2/3 data readout for CTX-009, now named tovecimig (a DLL4 x VEGF-A bispecific), in patients with biliary tract cancer (BTC) is on ...